KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy

Conditions:   Nasopharyngeal Carcinoma;   Recurrent or Metastatic
Intervention:   Drug: KL-A167 Injection
Sponsor:   Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Not yet recruiting

https://ift.tt/2GDytCi